Literature DB >> 12503812

Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.

L Aït Moussa1, C E Khassouani, B Hüe, M Jana, B Bégaud, R Soulaymani.   

Abstract

A large interindividual variability in drug acetylation is associated with genetic polymorphism of the polymorphic Type 2 N-acetyltransferase (NAT2), and an important interethnic difference has been frequently observed. However, few data on this polymorphism in the Moroccan population are available. In the present study the acetylator phenotype in 89 Moroccan patients with tuberculosis has been determined using isoniazid (INH) as metabolic probe. The subjects (69 women and 20 men between 18 and 77) were each given a 5 mg/kg oral dose of INH. Plasma concentration of INH and its metabolite, acetylisoniazid (ac.INH), were measured by high-performance liquid chromatography at 3 hours post dose. The plasma level ratio of acetylisoniazid to isoniazid (Rm), and the plasma level of acetylisoniazid as a percentage (%ac.INH) were used to express the activity of the polymorphic NAT2. The distribution of these 2 parameters in the studied population was clearly bimodal resulting in 2 distinct groups: slow acetylators (Rm < or = 0.84, %ac.INH < or = 45.64%), and fast acetylators (Rm > or = 1.29, %ac.INH > or = 56.26%) who accounted respectively for 61.8% and 38.2% of the population. The 2 approaches used showed a complete concordance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12503812     DOI: 10.5414/cpp40548

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  5 in total

1.  Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Authors:  Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Acetylation pharmacogenetics and renal function in diabetes mellitus patients.

Authors:  S O Banjoko; K S Akinlade
Journal:  Indian J Clin Biochem       Date:  2010-08-25

3.  Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.

Authors:  L Aït Moussa; O El Bouazzi; S Serragui; D Soussi Tanani; A Soulaymani; R Soulaymani
Journal:  Ther Adv Drug Saf       Date:  2016-09-07

4.  Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.

Authors:  Soukaina Guaoua; Ilham Ratbi; Fatima Zahra Laarabi; Siham Chafai Elalaoui; Imane Cherkaoui Jaouad; Amina Barkat; Abdelaziz Sefiani
Journal:  BMC Genet       Date:  2014-12-29       Impact factor: 2.797

5.  Isoniazid acetylation phenotypes in the Sudanese population; findings and implications.

Authors:  Monadil H Ali; Alian A Alrasheedy; Dan Kibuule; Mohamed Azmi Hassali; Brian Godman; Mohammed F Abdelwahab; Raef Y Abbadi
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.